Big Pharma Deal Hunters Target RNA Approaches In Race To Build Best Platforms

Companies Search For Novel Modalities, Enabling Technology

The potential for RNA medicines to achieve holy grail goals – reaching undruggable targets and bringing drugs to market faster – has Pfizer, Lilly, Novartis and others in a deal-making frame of mind. 

Ribonucleic acid strands consisting of nucleotides important for protein bio-synthesis
All types of RNA therapeutics and technology platforms are attracting pharma dollars • Source: Alamy

Big pharma companies are on the hunt for RNA-focused drug discovery and development technologies, not just to bring new drug candidates into their research and development pipelines but to build in-house platforms for discovering and developing their own novel RNA medicines that capitalize on the benefits of these newer modalities.

With the ability to reach previously undruggable targets and potentially bring drugs to market faster than small molecules and antibody...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.